APOE genotype and survival in men and women with Alzheimer's disease

Neurology

Volumn 58, Issue 7, 2002, Pages 1045-1050

  Dal Forno, G ^a,c,d   Carson, K A ^a,c   Brookmeyer, R ^a,c   Troncoso, J ^a,c   Kawas, C H ^a,c,e   Brandt, J ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

EID: 0037046184     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.7.1045     Document Type: Article

References (54)

1. Apolipoprotein E: High affinity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease
2. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease
3. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease
4. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
5. Apolipoprotein E ε4 distribution in late-onset Alzheimer's disease and in other amyloid forming diseases
6. Apolipoprotein E polymorphism and coronary artery disease
7. Linkage of late-onset Alzheimer's disease with apolipoprotein E type 4 on chromosome 19
8. Confirmation of the ε4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease
9. Apolipoprotein E polymorphism and Alzheimer's disease
10. Hypothesis: Microtubule instability and paired helical filaments formation in the Alzheimer's disease brain are related to apolipoprotein E genotype
11. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease
12. Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam study
13. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease
14. Apolipoprotein E non-cognitive symptoms and cognitive decline in late-onset Alzheimer's disease
15. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
16. Apolipoprotein E, survival in Alzheimer's disease patients and the competing risk of death and Alzheimer's disease
17. Apolipoprotein E epsilon 4 and disease progression in patients with late-onset Alzheimer's disease
18. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease
19. Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample
20. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease
21. Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease
22. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer's disease
23. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease
24. The apolipoprotein E ε2 allele is associated with an increased risk of earlyonset Alzheimer's disease and a reduced survival
25. Apolipoprotein E phenotype alone does not influence survival in Alzheimer's disease: A population-based longitudinal study
26. Neurological and psychiatric predictors of mortality in patients with Alzheimer's disease in California
27. The relationship between age, gender and cognitive performance in the very old: The effect of selective survival
28. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
29. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease
30. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
31. A reevaluation of the duration of survival after the onset of dementia
32. Psychogeriatric Dependency Rating Scales (PGDRS). A method of assessment for use by nurses
33. Survival and cause of death in Alzheimer's disease and multi-infarct dementia
34. Survival of outpatients with Alzheimer-type dementia
35. Women, myocardial infarction, and dementia in the very old
36. Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980-1990 prevalence findings
37. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study
38. Alzheimer's disease and other dementing illnesses in a defined United States population: Incidence rates and clinical features
39. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974
40. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham study
41. Familial aggregation in Alzheimer's disease: Comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations
42. Genetic transmission of Alzheimer's disease among families in a Dutch population based study
43. Assessing the risk of Alzheimer's disease in first-degree relatives of Alzheimer's disease cases
44. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What's in store for the "oldest old"?
45. Gender difference in apolipoprotein E-associated risk for familial Alzheimer's disease: A possible clue to the higher incidence of Alzheimer's disease in women
46. Alzheimer's disease: Interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity and age of onset
47. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects
48. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease
49. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
50. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
51. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case control study
52. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances